Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Sałaga M[au]:

Young GI angle: Effective data presentation. Salaga M et al. United European Gastroenterol J. (2017)

Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review. Sałaga M et al. Curr Treat Options Oncol. (2014)

Chronic abdominal pain in irritable bowel syndrome - current and future therapies. Zielińska A et al. Expert Rev Clin Pharmacol. (2018)

Search results

Items: 1 to 50 of 56

1.

Free Fatty Acid Receptors as new potential target in Colorectal Cancer.

Bartoszek A, Fichna J, Tarasiuk A, Binienda A, Fabisiak A, Krajewska JB, Mosińska P, Niewinna K, Salaga M.

Curr Drug Targets. 2019 Nov 12. doi: 10.2174/1389450120666191112141901. [Epub ahead of print]

PMID:
31721710
2.

Corrigendum to "Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system" [Biochem. Pharmacol. 161 (2019) 37-51].

Salaga M, Binienda A, Piscitelli F, Mokrowiecka A, Cygankiewicz AI, Verde R, Malecka-Panas E, Kordek R, Krajewska WM, Di Marzo V, Fichna J.

Biochem Pharmacol. 2019 Nov;169:113636. doi: 10.1016/j.bcp.2019.113636. Epub 2019 Sep 14. No abstract available.

PMID:
31526940
3.

Corrigendum to "The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome" [Eur. J. Pharmacol. (2018), 836 34-43].

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2019 Nov 5;862:172656. doi: 10.1016/j.ejphar.2019.172656. Epub 2019 Sep 10. No abstract available.

PMID:
31519354
4.

Dietary fatty acid content influences the expression of genes involved in the lipid turnover and inflammation in mouse colon and spleen.

Mosińska P, Tarasiuk A, Fabisiak A, Krajewska J, Niewinna K, Bartoszek A, Binienda A, Sałaga M, Fichna J.

Pharmacol Rep. 2019 Oct;71(5):899-908. doi: 10.1016/j.pharep.2019.07.010. Epub 2019 Jul 29.

5.

Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.

Zatorski H, Sałaga M, Fichna J.

Naunyn Schmiedebergs Arch Pharmacol. 2019 Nov;392(11):1321-1330. doi: 10.1007/s00210-019-01698-z. Epub 2019 Jul 29. Review.

PMID:
31359088
6.

UEG Young Talent Group: What do we do?

Acedo P, Heinrich H, van Herwaarden Y, Nakov R, Nitsche U, Rodríguez-Lago I, Salaga M, Skuja V.

United European Gastroenterol J. 2019 Feb;7(1):166-168. doi: 10.1177/2397847319826451. Epub 2019 Jan 30. No abstract available.

7.

High activity of endogenous opioid system protects against gastric damage development in mouse models of gastric mucosal injury.

Zatorski H, Salaga M, Zielińska M, Wasilewski A, Misicka A, Sacharczuk M, Fichna J.

Pharmacol Rep. 2019 Apr;71(2):218-224. doi: 10.1016/j.pharep.2018.10.011. Epub 2018 Oct 25.

PMID:
30785059
8.

High activity of the endogenous opioid system and acute but not chronic stress influence experimental colitis development in mice.

Zielinska M, Szymaszkiewicz A, Salaga M, Zatorski H, Wlodarczyk J, Jacenik D, Kordek R, Krajewska WM, Misicka A, Fichna J, Sacharczuk M.

J Physiol Pharmacol. 2018 Oct;69(5). doi: 10.26402/jpp.2018.5.11. Epub 2019 Jan 21.

9.

Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system.

Salaga M, Binienda A, Piscitelli F, Mokrowiecka A, Cygankiewicz AI, Verde R, Malecka-Panas E, Kordek R, Krajewska WM, Di Marzo V, Fichna J.

Biochem Pharmacol. 2019 Mar;161:37-51. doi: 10.1016/j.bcp.2019.01.001. Epub 2019 Jan 3. Erratum in: Biochem Pharmacol. 2019 Nov;169:113636.

PMID:
30611738
10.

Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain.

Zielińska A, Sałaga M, Włodarczyk M, Fichna J.

Int J Colorectal Dis. 2019 Feb;34(2):217-227. doi: 10.1007/s00384-018-3218-0. Epub 2018 Dec 19. Review.

11.

Novel peptide inhibitor of dipeptidyl peptidase IV (Tyr-Pro-D-Ala-NH2) with anti-inflammatory activity in the mouse models of colitis.

Salaga M, Binienda A, Draczkowski P, Kosson P, Kordek R, Jozwiak K, Fichna J.

Peptides. 2018 Oct;108:34-45. doi: 10.1016/j.peptides.2018.08.011. Epub 2018 Sep 1.

PMID:
30179653
12.

The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

Salaga M, Binienda A, Tichkule RB, Thakur GA, Makriyannis A, Storr M, Fichna J.

Eur J Pharmacol. 2018 Oct 5;836:34-43. doi: 10.1016/j.ejphar.2018.08.016. Epub 2018 Aug 17. Erratum in: Eur J Pharmacol. 2019 Nov 5;862:172656.

PMID:
30121173
13.

Chronic abdominal pain in irritable bowel syndrome - current and future therapies.

Zielińska A, Sałaga M, Włodarczyk M, Fichna J.

Expert Rev Clin Pharmacol. 2018 Jul;11(7):729-739. doi: 10.1080/17512433.2018.1494571. Epub 2018 Jul 9. Review.

PMID:
29957084
14.

Efficacy and Safety of Serotonin Receptor Ligands in the Treatment of Irritable Bowel Syndrome: A Review.

Binienda A, Storr M, Fichna J, Salaga M.

Curr Drug Targets. 2018;19(15):1774-1781. doi: 10.2174/1389450119666171227225408. Review.

PMID:
29284389
15.

FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue-derived hormone levels in mouse models mimicking constipation-predominant IBS.

Mosińska P, Jacenik D, Sałaga M, Wasilewski A, Cygankiewicz A, Sibaev A, Mokrowiecka A, Małecka-Panas E, Pintelon I, Storr M, Timmermans JP, Krajewska WM, Fichna J.

Neurogastroenterol Motil. 2018 May;30(5):e13272. doi: 10.1111/nmo.13272. Epub 2017 Dec 20.

PMID:
29266569
16.

Lysophosphatidylcholine and its phosphorothioate analogues potentiate insulin secretion via GPR40 (FFAR1), GPR55 and GPR119 receptors in a different manner.

Drzazga A, Kristinsson H, Sałaga M, Zatorski H, Koziołkiewicz M, Gendaszewska-Darmach E, Bergsten P.

Mol Cell Endocrinol. 2018 Sep 5;472:117-125. doi: 10.1016/j.mce.2017.12.002. Epub 2017 Dec 8.

PMID:
29225068
17.

The organisation and needs of young sections belonging to UEG National Societies: Results of a Europe-wide survey.

Ianiro G, Castro V, Dolak W, Ilie M, Holleran G, Salaga M, van Herwaarden Y, Burisch J; UEG Young Talent Group.

United European Gastroenterol J. 2017 Aug;5(5):750-755. doi: 10.1177/2050640617713936. Epub 2017 Jul 9.

18.

New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration.

Salaga M, Mokrowiecka A, Zielinska M, Malecka-Panas E, Kordek R, Kamysz E, Fichna J.

J Pharmacol Exp Ther. 2017 Oct;363(1):92-103. doi: 10.1124/jpet.117.242586. Epub 2017 Jul 19.

PMID:
28724693
19.

Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice.

Salaga M, Zatorski H, Zielińska M, Mosinska P, Timmermans JP, Kordek R, Storr M, Fichna J.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Oct;390(10):1015-1027. doi: 10.1007/s00210-017-1402-3. Epub 2017 Jul 14.

PMID:
28710683
20.

Young GI angle: Effective data presentation.

Salaga M, Leedham S.

United European Gastroenterol J. 2017 Jun;5(4):601-602. doi: 10.1177/2050640617709664. Epub 2017 May 22. No abstract available.

21.

Systemic Administration of Sialorphin Attenuates Experimental Colitis in Mice via Interaction With Mu and Kappa Opioid Receptors.

Salaga M, Mokrowiecka A, Jacenik D, Cygankiewicz AI, Malecka-Panas E, Kordek R, Krajewska WM, Sobocinska MK, Kamysz E, Fichna J.

J Crohns Colitis. 2017 Aug 1;11(8):988-998. doi: 10.1093/ecco-jcc/jjx043.

PMID:
28333341
22.

Anti-inflammatory effect of novel analogs of natural enkephalinase inhibitors in a mouse model of experimental colitis.

Kamysz E, Sałaga M, Sobocińska M, Giełdoń A, Fichna J.

Future Med Chem. 2016 Dec;8(18):2231-2243. Epub 2016 Nov 15.

PMID:
27845570
23.

Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice.

Zielińska M, Jarmuż A, Sałaga M, Kordek R, Laudon M, Storr M, Fichna J.

Naunyn Schmiedebergs Arch Pharmacol. 2016 May;389(5):511-9. doi: 10.1007/s00210-016-1214-x. Epub 2016 Feb 22.

24.

Neuropharmacological characterization of the oneirogenic Mexican plant Calea zacatechichi aqueous extract in mice.

Sałaga M, Fichna J, Socała K, Nieoczym D, Pieróg M, Zielińska M, Kowalczuk A, Wlaź P.

Metab Brain Dis. 2016 Jun;31(3):631-41. doi: 10.1007/s11011-016-9794-1. Epub 2016 Jan 28.

25.

RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives.

Salaga M, Storr M, Martemyanov KA, Fichna J.

Bioessays. 2016 Apr;38(4):344-54. doi: 10.1002/bies.201500118. Epub 2016 Jan 28. Review.

26.

Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review.

Mosińska P, Salaga M, Fichna J.

Expert Opin Investig Drugs. 2016;25(3):275-86. doi: 10.1517/13543784.2016.1142532. Epub 2016 Feb 4. Review.

PMID:
26765585
27.

Mixed MOP/DOP agonist biphalin elicits anti-transit effect in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.

Zielińska M, Jarmuż A, Sałaga M, Lipkowski AW, Fichna J.

Pharmacol Rep. 2016 Feb;68(1):32-6. doi: 10.1016/j.pharep.2015.06.001. Epub 2015 Jun 12.

PMID:
26721348
28.

Encenicline, an α7 Nicotinic Acetylcholine Receptor Partial Agonist, Reduces Immune Cell Infiltration in the Colon and Improves Experimental Colitis in Mice.

Salaga M, Blomster LV, Piechota-Polańczyk A, Zielińska M, Jacenik D, Cygankiewicz AI, Krajewska WM, Mikkelsen JD, Fichna J.

J Pharmacol Exp Ther. 2016 Jan;356(1):157-69. doi: 10.1124/jpet.115.228205. Epub 2015 Oct 13.

PMID:
26462538
29.

Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice.

Zielińska M, Ben Haddou T, Cami-Kobeci G, Sałaga M, Jarmuż A, Padysz M, Kordek R, Spetea M, Husbands SM, Fichna J.

Eur J Pharmacol. 2015 Oct 15;765:582-90. doi: 10.1016/j.ejphar.2015.09.021. Epub 2015 Sep 25.

30.

Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome.

Sałaga M, Kowalczuk A, Zielinska M, Błażewicz A, Fichna J.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Oct;388(10):1069-77. doi: 10.1007/s00210-015-1142-1. Epub 2015 Jun 12.

31.

Salvinorin A analogues PR-37 and PR-38 attenuate compound 48/80-induced itch responses in mice.

Salaga M, Polepally PR, Zielinska M, Marynowski M, Fabisiak A, Murawska N, Sobczak K, Sacharczuk M, Do Rego JC, Roth BL, Zjawiony JK, Fichna J.

Br J Pharmacol. 2015 Sep;172(17):4331-41. doi: 10.1111/bph.13212. Epub 2015 Jul 14.

32.

[Genetic factors in pathogenesis, course and treatment of inflammatory bowel diseases].

Zatorski H, Sałaga M, Zielińska M, Fichna J.

Postepy Hig Med Dosw (Online). 2015 Mar 17;69:335-44. Review. Polish.

33.

Experimental colitis in mice is attenuated by topical administration of chlorogenic acid.

Zatorski H, Sałaga M, Zielińska M, Piechota-Polańczyk A, Owczarek K, Kordek R, Lewandowska U, Chen C, Fichna J.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Jun;388(6):643-51. doi: 10.1007/s00210-015-1110-9. Epub 2015 Mar 7.

34.

T cell-activated signaling pathways and locally produced cytokines as potential targets in celiac disease.

Piechota-Polańczyk A, Sałaga M, Huk I.

Curr Drug Targets. 2015;16(3):226-32. Review.

PMID:
25738293
35.

Orally administered novel cyclic pentapeptide P-317 alleviates symptoms of diarrhoea-predominant irritable bowel syndrome.

Zielińska M, Chen C, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, Sałaga M, Małecka-Panas E, Wlaź P, Krajewska WM, Fichna J.

J Pharm Pharmacol. 2015 Feb;67(2):244-54. doi: 10.1111/jphp.12335. Epub 2014 Dec 17.

PMID:
25515402
36.

Role of transient receptor potential channels in intestinal inflammation and visceral pain: novel targets in inflammatory bowel diseases.

Zielińska M, Jarmuż A, Wasilewski A, Sałaga M, Fichna J.

Inflamm Bowel Dis. 2015 Feb;21(2):419-27. doi: 10.1097/MIB.0000000000000234. Review.

PMID:
25437822
37.

Novel orally available salvinorin A analog PR-38 protects against experimental colitis and reduces abdominal pain in mice by interaction with opioid and cannabinoid receptors.

Sałaga M, Polepally PR, Zakrzewski PK, Cygankiewicz A, Sobczak M, Kordek R, Zjawiony JK, Krajewska WM, Fichna J.

Biochem Pharmacol. 2014 Dec 15;92(4):618-26. doi: 10.1016/j.bcp.2014.09.018. Epub 2014 Oct 6.

PMID:
25265540
38.

Anti-inflammatory and antinociceptive action of the dimeric enkephalin peptide biphalin in the mouse model of colitis: new potential treatment of abdominal pain associated with inflammatory bowel diseases.

Sobczak M, Pilarczyk A, Jonakowski M, Jarmuż A, Sałaga M, Lipkowski AW, Fichna J.

Peptides. 2014 Oct;60:102-6. doi: 10.1016/j.peptides.2014.08.005. Epub 2014 Aug 20.

PMID:
25151037
39.

Anti-inflammatory action of a novel orally available peptide 317 in mouse models of inflammatory bowel diseases.

Sobczak M, Zakrzewski PK, Cygankiewicz AI, Mokrowiecka A, Chen C, Sałaga M, Małecka-Panas E, Kordek R, Krajewska WM, Fichna J.

Pharmacol Rep. 2014 Oct;66(5):741-50. doi: 10.1016/j.pharep.2014.03.007. Epub 2014 Apr 4.

PMID:
25149976
40.

Cross-talk between serotonin and cannabinoid signaling in the gut, new insights and future perspectives.

Salaga M, Storr M, Fichna J.

Pain. 2014 Oct;155(10):2204-5. doi: 10.1016/j.pain.2014.08.002. Epub 2014 Aug 7. No abstract available.

PMID:
25109671
41.

Polyphenol extract from evening primrose pomace alleviates experimental colitis after intracolonic and oral administration in mice.

Sałaga M, Lewandowska U, Sosnowska D, Zakrzewski PK, Cygankiewicz AI, Piechota-Polańczyk A, Sobczak M, Mosinska P, Chen C, Krajewska WM, Fichna J.

Naunyn Schmiedebergs Arch Pharmacol. 2014 Nov;387(11):1069-78. doi: 10.1007/s00210-014-1025-x. Epub 2014 Jul 31.

42.

Activation of the endogenous nociceptin system by selective nociceptin receptor agonist SCH 221510 produces antitransit and antinociceptive effect: a novel strategy for treatment of diarrhea-predominant IBS.

Fichna J, Sobczak M, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, Cenac N, Sałaga M, Timmermans JP, Vergnolle N, Małecka-Panas E, Krajewska WM, Storr M.

Neurogastroenterol Motil. 2014 Nov;26(11):1539-50. doi: 10.1111/nmo.12390. Epub 2014 Jul 15.

PMID:
25041572
43.

Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.

Sałaga M, Polepally PR, Sobczak M, Grzywacz D, Kamysz W, Sibaev A, Storr M, Do Rego JC, Zjawiony JK, Fichna J.

J Pharmacol Exp Ther. 2014 Jul;350(1):69-78. doi: 10.1124/jpet.114.214239.

PMID:
24891526
44.

Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.

Sobczak M, Cami-Kobeci G, Sałaga M, Husbands SM, Fichna J.

Eur J Pharmacol. 2014 Aug 5;736:63-9. doi: 10.1016/j.ejphar.2014.04.038. Epub 2014 May 6.

45.

Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review.

Sałaga M, Zatorski H, Sobczak M, Chen C, Fichna J.

Curr Treat Options Oncol. 2014 Sep;15(3):405-20. doi: 10.1007/s11864-014-0288-2. Review.

46.

Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH).

Sałaga M, Mokrowiecka A, Zakrzewski PK, Cygankiewicz A, Leishman E, Sobczak M, Zatorski H, Małecka-Panas E, Kordek R, Storr M, Krajewska WM, Bradshaw HB, Fichna J.

J Crohns Colitis. 2014 Sep;8(9):998-1009. doi: 10.1016/j.crohns.2014.01.025. Epub 2014 Feb 14.

47.

Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides.

Fichna J, Sałaga M, Stuart J, Saur D, Sobczak M, Zatorski H, Timmermans JP, Bradshaw HB, Ahn K, Storr MA.

Neurogastroenterol Motil. 2014 Apr;26(4):470-81. doi: 10.1111/nmo.12272. Epub 2013 Dec 3.

PMID:
24460851
48.

Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study.

Fichna J, Wood JT, Papanastasiou M, Vadivel SK, Oprocha P, Sałaga M, Sobczak M, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, Małecka-Panas E, Krajewska WM, Kościelniak P, Makriyannis A, Storr MA.

PLoS One. 2013 Dec 27;8(12):e85073. doi: 10.1371/journal.pone.0085073. eCollection 2013.

49.

Anti-inflammatory and antinociceptive action of an orally available nociceptin receptor agonist SCH 221510 in a mouse model of inflammatory bowel diseases.

Sobczak M, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, Sałaga M, Storr M, Kordek R, Małecka-Panas E, Krajewska WM, Fichna J.

J Pharmacol Exp Ther. 2014 Mar;348(3):401-9. doi: 10.1124/jpet.113.209825. Epub 2013 Dec 17.

PMID:
24345466
50.

Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.

Sałaga M, Sobczak M, Fichna J.

Eur J Pharm Sci. 2014 Feb 14;52:173-9. doi: 10.1016/j.ejps.2013.11.012. Epub 2013 Nov 23. Review.

PMID:
24275607

Supplemental Content

Loading ...
Support Center